Inlay osmotic pump tablets containing metformin and glipizide

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Diabetes Therapeutics

Background:

• Diabetes mellitus requires strict glycemic control to prevent microvascular and macrovascular complications.
• Conventional drug delivery systems may not provide optimal therapeutic outcomes for managing diabetes.
• Controlled-release formulations offer a promising approach to enhance diabetes therapy.

Purpose of the Study:

• To develop and characterize an inlay osmotic pump tablet (IOPT) for the combined delivery of glipizide (GLZ) and metformin HCl (MET).
• To achieve a specific release profile: >75% GLZ within 2 hours, followed by sustained MET release for up to 12 hours.
• To optimize formulation variables for controlled drug release and improved physicochemical properties.

Main Methods:

• HP-β-CD was used to enhance GLZ solubility.
• MET was spray-dried with HPMC A15C to modify its release and properties.
• Osmotic system variables including osmagents, polymer concentration, orifice diameter, and coating composition were investigated.
• Drug release kinetics were analyzed using parameters like G(75%), t(LMET), Q(10 h), and RSQ(ZERO).

Main Results:

• The IOPT successfully achieved the target release profiles for both GLZ and MET.
• Sodium carbonate and sodium chloride effectively modified GLZ release rates.
• Dual-coating and hydrophilic polymers were used to adjust MET release rates.
• Formulation variables significantly influenced the drug release characteristics.

Conclusions:

• The developed inlay osmotic system provides a viable strategy for the controlled co-delivery of GLZ and MET.
• This advanced drug delivery system holds potential for effective multidrug therapy in diabetes management.
• The IOPT offers a promising approach to improve patient compliance and therapeutic efficacy in diabetes treatment.